NAMS Key Statistics, Chart & Performance
The current stock price of NAMS is 34.46 USD. In the past month the price decreased by -6.61%. In the past year, price increased by 34.19%.
NAMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.62 | 394.52B | ||
| AMGN | AMGEN INC | 14.84 | 174.80B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 149.91B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.04 | 119.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.31 | 81.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 758.57 | 51.11B | ||
| INSM | INSMED INC | N/A | 36.98B | ||
| NTRA | NATERA INC | N/A | 32.78B | ||
| BIIB | BIOGEN INC | 10.82 | 26.57B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.36 | 22.01B | ||
| INCY | INCYTE CORP | 16.16 | 20.37B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About NAMS
Company Profile
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 68 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
Company Info
NEWAMSTERDAM PHARMA CO NV
Gooimeer 2-35
Naarden NOORD-HOLLAND NL
Employees: 68
Phone: 31352062971
NEWAMSTERDAM PHARMA CO NV / NAMS FAQ
What does NAMS do?
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 68 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
What is the current price of NAMS stock?
The current stock price of NAMS is 34.46 USD. The price increased by 2.93% in the last trading session.
What is the dividend status of NEWAMSTERDAM PHARMA CO NV?
NAMS does not pay a dividend.
What is the ChartMill rating of NEWAMSTERDAM PHARMA CO NV stock?
NAMS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the upcoming earnings date for NEWAMSTERDAM PHARMA CO NV?
NEWAMSTERDAM PHARMA CO NV (NAMS) will report earnings on 2026-02-24, after the market close.
Who owns NEWAMSTERDAM PHARMA CO NV?
You can find the ownership structure of NEWAMSTERDAM PHARMA CO NV (NAMS) on the Ownership tab.
NAMS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NAMS. When comparing the yearly performance of all stocks, NAMS is one of the better performing stocks in the market, outperforming 70.37% of all stocks.
NAMS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NAMS Forecast & Estimates
21 analysts have analysed NAMS and the average price target is 48.96 USD. This implies a price increase of 42.08% is expected in the next year compared to the current price of 34.46.